Is sitagliptin effective for the treatment of COVID-19?

Basit Öğe Kaydı
dc.authoridBahçecioğlu, Ömer Faruk/0000-0002-4045-4555
dc.authoridMemiş, Hasan/0000-0001-7158-1795
dc.authoridDurmus, Mefkure/0000-0001-9745-4196
dc.authoridÇakır, Ahmet/0000-0002-9843-1604
dc.authoridCakir, Ahmet/0000-0003-1590-585X
dc.authorwosidBahçecioğlu, Ömer Faruk/AAA-7477-2021
dc.authorwosidMemiş, Hasan/AAA-9596-2022
dc.authorwosidDurmus, Mefkure/ISR-9328-2023
dc.authorwosidÇakır, Ahmet/ABH-5565-2020
dc.contributor.authorMemis, Hasan
dc.contributor.authorCakir, Ahmet
dc.contributor.authorDurmus, Mefkure
dc.contributor.authorGok, Selim
dc.contributor.authorBahcecioglu, Omer Faruk
dc.date.accessioned2024-08-04T20:49:15Z
dc.date.available2024-08-04T20:49:15Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.doi10.1136/ejhpharm-2021-002702
dc.identifier.endpageE6en_US
dc.identifier.issn2047-9956
dc.identifier.issn2047-9964
dc.identifier.issue6en_US
dc.identifier.pmid33504509en_US
dc.identifier.scopus2-s2.0-85100081948en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpageE6en_US
dc.identifier.urihttps://doi.org/10.1136/ejhpharm-2021-002702
dc.identifier.urihttps://hdl.handle.net/11616/99741
dc.identifier.volume29en_US
dc.identifier.wosWOS:000728307200001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBmj Publishing Groupen_US
dc.relation.ispartofEuropean Journal of Hospital Pharmacyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keywords]en_US
dc.titleIs sitagliptin effective for the treatment of COVID-19?en_US
dc.typeLetteren_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu